Sanofi shares slide as FDA delays MS drug decision and late-stage trial disappoints

Core Viewpoint - Shares of French pharmaceutical group Sanofi experienced a significant decline following the announcement of another delay in the US regulatory decision for its experimental multiple sclerosis drug tolebrutinib [1] Group 1 - Sanofi's stock price fell sharply on Monday due to the regulatory delay [1] - The delay pertains to the US regulatory decision regarding the multiple sclerosis drug tolebrutinib [1]